BRCA1 and BRCA2 mutations in Turkish familial and non-familial ovarian cancer patients: a high incidence of mutations in non-familial cases

Ovarian cancer is a clinically important cancer in Turkey. The contribution of BRCA1 and BRCA2 to ovarian cancer in Turkish patients has not previously been described. In this study we investigated the presence of BRCA1 and BRCA2 mutations in 102 consecutively ascertained, hospital‐based, ovarian ca...

Full description

Saved in:

Bibliographic Details
Published in:	Human mutation Vol. 20; no. 1; pp. 28 - 34
Main Authors:	Yazici, Hulya, Glendon, Gordon, Yazici, Hilal, Burnie, Steve J., Saip, Pánar, Buyru, Faruk, Bengisu, Ergin, Andrulis, Irene L., Dalay, Nejat, Ozcelik, Hilmi
Format:	Journal Article
Language:	English
Published:	New York Wiley Subscription Services, Inc., A Wiley Company 01-07-2002 Hindawi Limited
Subjects:	Adult Aged BRCA1 BRCA1 Protein - genetics BRCA2 BRCA2 Protein - genetics DNA Mutational Analysis DNA, Neoplasm - chemistry DNA, Neoplasm - genetics Family Health Female germline hereditary cancer Humans Incidence Middle Aged Mutation mutation screening ovarian cancer Ovarian Neoplasms - epidemiology Ovarian Neoplasms - genetics Ovarian Neoplasms - pathology sporadic Turkey - epidemiology Turkish Turkey
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Ovarian cancer is a clinically important cancer in Turkey. The contribution of BRCA1 and BRCA2 to ovarian cancer in Turkish patients has not previously been described. In this study we investigated the presence of BRCA1 and BRCA2 mutations in 102 consecutively ascertained, hospital‐based, ovarian cancer cases. Four out of 15 (26.7%, 95% confidence interval (CI), 7.8%–55.1%) familial cases were found to carry mutations in BRCA1. Thirteen of the 87 (14.9%, 95% CI, 7.5%–22.4%) non‐familial cases had BRCA1 and BRCA2 mutations, six in BRCA1, and seven in BRCA2. We have further studied the non‐familial ovarian cancer cases to determine which subgroups have a likelihood of carrying clinically important mutations. Our study shows that those Turkish ovarian cancer patients with serous histopathology harbor a high proportion of mutations (12/58, 20.7%, 95% CI, 10.3%–31.1%) compared to all non‐familial cases (14.9%) regardless of pathology. Within the serous sub‐group, those that were also diagnosed below age 50 have an even greater percentage of mutations (8/28, 28.6%, 95% CI, 11.8%–45.3%). Our findings demonstrate that a substantial proportion of Turkish ovarian cancer patients, both with and without a family history, carry BRCA1 and BRCA2 mutations, demonstrating the importance of BRCA1 and BRCA2 in the development of ovarian cancer in this population. © 2002 Wiley‐Liss, Inc.
Bibliography:	NATO - No. CRG960130 Istanbul University Research Fund - No. UP-3-190397 State Planning Organization in Turkey - No. 97K121700 ArticleID:HUMU10090 istex:9C5C58888096E14960107E705D3F9D3B6C8F91D0 ark:/67375/WNG-81M9KXC0-R ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1059-7794 1098-1004
DOI:	10.1002/humu.10090